Today: 11 June 2026
Wells Fargo stock rises today as traders eye jobs report, big-bank earnings kickoff
2 January 2026
1 min read

Wells Fargo stock rises today as traders eye jobs report, big-bank earnings kickoff

NEW YORK, January 2, 2026, 13:55 ET — Regular session

  • Wells Fargo shares were up about 1.2% in early afternoon trading.
  • Bank stocks were mixed, with the bank ETF higher while the broader financial sector slipped.
  • Investors are watching the Jan. 9 U.S. jobs report and Wells Fargo’s Jan. 14 earnings next.

Wells Fargo & Company (WFC) shares rose 1.2% to $94.35 in early afternoon trading on Friday, after swinging between $92.81 and $94.43.

The move comes as investors head into the first full trading week of 2026 with the U.S. jobs report due Jan. 9 and consumer price data on Jan. 13, the same day JPMorgan is set to open the big-bank earnings season. The Fed cut rates at each of its last three meetings of 2025, and fed funds futures — derivatives that track where traders see policy rates — suggest little chance of another cut at the late-January meeting but nearly a 50% chance of a quarter-point reduction in March. “The market is looking for direction,” said Matthew Maley, chief market strategist at Miller Tabak. Reuters

That rate backdrop matters for Wells Fargo and other lenders because it influences net interest margin — the spread between what banks earn on loans and pay on deposits — and can also change credit demand as borrowing costs move.

In the sector, the SPDR S&P Bank ETF (KBE) was up about 0.3%, while the Financial Select Sector SPDR Fund (XLF) was down about 0.3%. Shares of peers JPMorgan (JPM) and Bank of America (BAC) were modestly higher, while Citigroup (C) and Goldman Sachs (GS) also traded up.

The broader market was little changed after early gains faded, with investors keeping an eye on the path for U.S. interest rates and other policy risks as 2026 begins.

Wells Fargo has said it plans to report fourth-quarter 2025 results on Jan. 14.

For Wells Fargo’s report, investors are likely to focus on net interest income, expense discipline and credit costs, along with any signal on loan growth as the economy slows and rate cuts remain on the table.

Technically, the stock ended 2025 at $93.20, about 2.8% below its 52-week high of $95.85 set on Dec. 24, MarketWatch data showed. Traders are watching whether the shares can push back through that recent peak and hold the late-December range as support.

Wells Fargo’s longer-term story has also been shaped by regulators lifting the bank’s $1.95 trillion asset cap in June 2025, a key constraint that had limited balance-sheet growth after the lender’s sales-practices scandal.

Beyond earnings, Wells Fargo’s investor events calendar lists a presentation at the UBS Financial Services Conference on Feb. 10, an appearance that can bring fresh color on costs, credit and rate sensitivity.

Stock Market Today

  • Live Cattle Futures Edge Higher Amid Mixed USDA Beef Prices
    June 11, 2026, 10:54 AM EDT. Live cattle futures rose by $1.45 to $1.60 across most front months on Wednesday, with December delivery slightly down. Feeder cattle futures gained $2.40 to $2.90 by midday. Open interest increased by 1,293 contracts. Managed money trimmed net long positions in live cattle futures and options by 7,083 contracts, totaling 101,265, while feeder cattle spec funds reduced holdings by 470 contracts. USDA reported a decline in wholesale boxed beef prices, with Choice boxes down $1.68 to $359.36 and Select down $3.15 to $344.88. Federally inspected cattle slaughter rose to an estimated 123,000 head Wednesday, exceeding last week but falling short of last year. The mixed data signals ongoing volatility in cattle markets as traders assess supply and demand factors.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Hubble spots odd triple jets on interstellar comet 3I/ATLAS as radio search finds no alien signal
Previous Story

Hubble spots odd triple jets on interstellar comet 3I/ATLAS as radio search finds no alien signal

Caterpillar stock jumps 4% as Wolfe lifts target to $670; investors brace for Jan. 9 jobs report
Next Story

Caterpillar stock jumps 4% as Wolfe lifts target to $670; investors brace for Jan. 9 jobs report

Go toTop